Download PDF
Aktuelle Dermatologie 2013; 39(12): 529-538
DOI: 10.1055/s-0033-1358946
Fort- und Weiterbildung
© Georg Thieme Verlag KG Stuttgart · New York

Autoinflammatorische Krankheiten – Von der Biochemie zur klinischen Anwendung

Autoinflammatory Syndromes – from Research to Clinical Applications
K. Welsch
Zentrum für seltene Erkrankungen, Universitäts-Hautklinik, Tübingen
,
A. S. Yazdi
Zentrum für seltene Erkrankungen, Universitäts-Hautklinik, Tübingen
› Author Affiliations
Further Information

Publication History

Publication Date:
12 December 2013 (online)

Also available at
   Permissions and Reprints

Lernziele

Kenntnisse über

  • angeborene Immunität

  • Interleukin-1-Zytokine

  • Pathogenese der Fiebersyndrome

  • Typen von Fiebersyndromen

  • Therapie von autoinflammatorischen Erkrankungen

 

  • Literatur

  • 1 Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 781-801
    PubMedGoogle Scholar
  • 2 Martinon F, Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol 2005; 26: 447-454
    CrossrefPubMedGoogle Scholar
  • 3 Janeway Jr CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216
    CrossrefPubMedGoogle Scholar
  • 4 Hampe J, Cuthbert A, Croucher PJ et al. Association between insertion mutation in NOD2 gene and Crohn’s disease in German and British populations. Lancet 2001; 357: 1925-1928
    CrossrefPubMedGoogle Scholar
  • 5 Miceli-Richard C, Lesage S, Rybojad M et al. CARD15 mutations in Blau syndrome. Nat Genet 2001; 29: 19-20
    CrossrefPubMedGoogle Scholar
  • 6 Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519-550
    CrossrefPubMedGoogle Scholar
  • 7 Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-2147
    PubMedGoogle Scholar
  • 8 Thornberry NA, Bull HG, Calaycay JR et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 1992; 356: 768-774
    CrossrefPubMedGoogle Scholar
  • 9 Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10: 417-426
    CrossrefPubMedGoogle Scholar
  • 10 Mariathasan S, Weiss DS, Newton K et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006; 440: 228-232
    CrossrefPubMedGoogle Scholar
  • 11 Martinon F, Petrilli V, Mayor A et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-241
    CrossrefPubMedGoogle Scholar
  • 12 Duewell P, Kono H, Rayner KJ et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464: 1357-1361
    CrossrefPubMedGoogle Scholar
  • 13 Zhou R, Tardivel A, Thorens B et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010; 11: 136-140
    CrossrefPubMedGoogle Scholar
  • 14 Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821-832
    CrossrefPubMedGoogle Scholar
  • 15 Larsen CM, Faulenbach M, Vaag A et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1526
    CrossrefPubMedGoogle Scholar
  • 16 So A, De Smedt T, Revaz S et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9: R28
    CrossrefPubMedGoogle Scholar
  • 17 Johansen C, Moeller K, Kragballe K et al. The activity of caspase-1 is increased in lesional psoriatic epidermis. J Invest Dermatol 2007; 127: 2857-2864
    CrossrefPubMedGoogle Scholar
  • 18 Hong JB, Prucha H, Melnik B et al. Uncommon acne-associated syndromes and their significance in understanding the pathogenesis of acne. Hautarzt 2013; 64: 274-279
    CrossrefPubMedGoogle Scholar
  • 19 Gul A, Tugal-Tutkun I, Dinarello CA et al. Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet’s disease: an open-label pilot study. Ann Rheum Dis 2012; 71: 563-566
    CrossrefPubMedGoogle Scholar
  • 20 Jankovic D, Ganesan J, Bscheider M et al. The Nlrp3 inflammasome regulates acute graft-versus-host disease. J Exp Med 2013; 210: 1899-1910
    CrossrefPubMedGoogle Scholar
  • 21 Almeida de Jesus A, Goldbach-Mansky R. Monogenic autoinflammatory diseases: concept and clinical manifestations. Clin Immunol 2013; 147: 155-174
    CrossrefPubMedGoogle Scholar
  • 22 The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 1997; 90: 797-807
    CrossrefPubMedGoogle Scholar
  • 23 Tunc R, Uluhan A, Melikoglu M et al. A reassessment of the International Study Group criteria for the diagnosis (classification) of Behcet’s syndrome. Clin Exp Rheumatol 2001; 19: 45-47
    PubMedGoogle Scholar
  • 24 Feldmeyer L. Autoinflammatory syndromes in dermatology. Rev Med Suisse 2012; 8: 756-758 760 – 761
    PubMedGoogle Scholar
  • 25 Simon A, van der Meer JW, Drenth JP. Familial Mediterranean fever – a not so unusual cause of abdominal pain. Best Pract Res Clin Gastroenterol 2005; 19: 199-213
    CrossrefPubMedGoogle Scholar
  • 26 Wilbur K, Makowsky M. Colchicine myotoxicity: case reports and literature review. Pharmacotherapy 2004; 24: 1784-1792
    CrossrefPubMedGoogle Scholar
  • 27 van der Meer JW, Vossen JM, Radl J et al. Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. Lancet 1984; 1: 1087-1090
    PubMedGoogle Scholar
  • 28 van der Hilst JC, Bodar EJ, Barron KS et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 2008; 87: 301-310
    CrossrefPubMedGoogle Scholar
  • 29 Aksentijevich I, Galon J, Soares M et al. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 2001; 69: 301-314
    CrossrefPubMedGoogle Scholar
  • 30 McDermott MF, Aksentijevich I, Galon J et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97: 133-144
    CrossrefPubMedGoogle Scholar
  • 31 Bulua AC, Simon A, Maddipati R et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 2011; 208: 519-533
    CrossrefPubMedGoogle Scholar
  • 32 Braun-Falco M, Ruzicka T. Skin manifestations in autoinflammatory syndromes. J Dtsch Dermatol Ges 2011; 9: 232-246
    PubMedGoogle Scholar
  • 33 Gattorno M, Pelagatti MA, Meini A et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008; 58: 1516-1520
    CrossrefPubMedGoogle Scholar
  • 34 Aksentijevich I, Nowak M, Mallah M et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002; 46: 3340-3348
    CrossrefPubMedGoogle Scholar
  • 35 Hoffman HM, Wright FA, Broide DH et al. Identification of a locus on chromosome 1q44 for familial cold urticaria. Am J Hum Genet 2000; 66: 1693-1698
    CrossrefPubMedGoogle Scholar
  • 36 Hoffman HM, Mueller JL, Broide DH et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29: 301-305
    CrossrefPubMedGoogle Scholar
  • 37 Loock J, Lamprecht P, Timmann C et al. Genetic predisposition (NLRP3 V198M mutation) for IL-1-mediated inflammation in a patient with Schnitzler syndrome. J Allergy Clin Immunol 2010; 125: 500-502
    CrossrefPubMedGoogle Scholar
  • 38 Kuemmerle-Deschner JB, Wittkowski H, Tyrrell PN et al. Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. Arthritis Res Ther 2013; 15: R64
    CrossrefPubMedGoogle Scholar
  • 39 Koné-Paut I, Lachmann HJ, Kuemmerle-Deschner JB et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther 2011; 13: R202
    CrossrefPubMedGoogle Scholar
  • 40 Hawkins PN, Lachmann HJ, Aganna E et al. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004; 50: 607-612
    CrossrefPubMedGoogle Scholar
  • 41 Kuemmerle-Deschner JB, Tyrrell PN, Koetter I et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum 2011; 63: 840-849
    CrossrefPubMedGoogle Scholar
  • 42 Goldbach-Mansky R, Dailey NJ, Canna SW et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006; 355: 581-592
    CrossrefPubMedGoogle Scholar
  • 43 Shoham NG, Centola M, Mansfield E et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci USA 2003; 100: 13501-13506
    CrossrefPubMedGoogle Scholar
  • 44 Lindor NM, Arsenault TM, Solomon H et al. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc 1997; 72: 611-615
    CrossrefPubMedGoogle Scholar
  • 45 Smith EJ, Allantaz F, Bennett L et al. Clinical, Molecular, and Genetic Characteristics of PAPA Syndrome: A Review. Curr Genomics 2010; 11: 519-527
    CrossrefPubMedGoogle Scholar
  • 46 Tofteland ND, Shaver TS. Clinical efficacy of etanercept for treatment of PAPA syndrome. J Clin Rheumatol 2010; 16: 244-245
    CrossrefPubMedGoogle Scholar
  • 47 Brenner M, Ruzicka T, Plewig G et al. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009; 161: 1199-1201
    CrossrefPubMedGoogle Scholar
  • 48 Braun-Falco M, Kovnerystyy O, Lohse P et al. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) – a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol 2012; 66: 409-415
    CrossrefPubMedGoogle Scholar
  • 49 Kolly L, Busso N, von Scheven-Gete A et al. Periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome is linked to dysregulated monocyte IL-1beta production. J Allergy Clin Immunol 2013; 131: 1635-1643
    CrossrefPubMedGoogle Scholar
  • 50 Ter Haar N, Lachmann H, Ozen S et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2013; 72: 678-685
    CrossrefPubMedGoogle Scholar
  • 51 Simon A, Asli B, Braun-Falco M et al. Schnitzler’s syndrome: diagnosis, treatment, and follow-up. Allergy 2013; 68: 562-568
    CrossrefPubMedGoogle Scholar
  • 52 Volz T, Wolbing F, Fischer J et al. Dermal interleukin-1 expression and effective and long-lasting therapy with interleukin-1 receptor antagonist anakinra in Schnitzler syndrome. Acta Derm Venereol 2012; 92: 393-394
    CrossrefPubMedGoogle Scholar
  • 53 de Koning HD, Bodar EJ, van der Meer JW et al. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 2007; 37: 137-148
    CrossrefPubMedGoogle Scholar
  • 54 Aksentijevich I, Masters SL, Ferguson PJ et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360: 2426-2437
    CrossrefPubMedGoogle Scholar
  • 55 Minkis K, Aksentijevich I, Goldbach-Mansky R et al. Interleukin 1 receptor antagonist deficiency presenting as infantile pustulosis mimicking infantile pustular psoriasis. Arch Dermatol 2012; 148: 747-752
    PubMedGoogle Scholar
  • 56 Schnellbacher C, Ciocca G, Menendez R et al. Deficiency of Interleukin-1 Receptor Antagonist Responsive to Anakinra. Pediatr Dermatol 2012; DOI: 10.1111/j.1525-1470.2012.01725.x.
    PubMedGoogle Scholar
  • 57 Marrakchi S, Guigue P, Renshaw BR et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365: 620-628
    CrossrefPubMedGoogle Scholar
  • 58 Pétrilli V, Dostert C, Muruve DA et al. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunology 2007; 19: 615-622
    PubMedGoogle Scholar